SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics
STSA Price/Volume Stats
Current price | $1.10 | 52-week high | $8.08 |
Prev. close | $1.11 | 52-week low | $0.59 |
Day low | $1.01 | Volume | 1,829,700 |
Day high | $1.14 | Avg. volume | 701,788 |
50-day MA | $0.97 | Dividend yield | N/A |
200-day MA | $2.38 | Market Cap | 36.47M |
STSA Stock Price Chart Interactive Chart >
SATSUMA PHARMACEUTICALS, INC. (STSA) Company Bio
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Latest STSA News From Around the Web
Below are the latest news stories about SATSUMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate STSA as an investment opportunity.
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineJanuary 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma lev |
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingSOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-p |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! |
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?Prometheus Biosciences (RXDX) stock is on the rise Monday after the company revealed a $10.8 billion acquisition deal with Merck (MRK). |
Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?Satsuma Pharmaceuticals (STSA) stock is taking off on Monday after revealing an acquisition deal with Shin Nippon Biomedical Laboratories. |
STSA Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 54.34% |
3-year | -80.87% |
5-year | N/A |
YTD | N/A |
2023 | 0.00% |
2022 | -80.00% |
2021 | -2.39% |
2020 | -76.58% |
2019 | N/A |
Loading social stream, please wait...